The Effects of KW-3902, an Adenosine A1-Receptor Antagonist,on Diuresis and Renal Function in Patients With Acute Decompensated Heart Failure and Renal Impairment or Diuretic Resistance
Michael M. Givertz, MD, FACC*,*,
Barry M. Massie, MD, FACC ,
Tara K. Fields, BA ,
Leeanne L. Pearson, RN, BS,
Howard C. Dittrich, MD, FACC, on behalf of the CKI-201 and CKI-202 Investigators
* Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts
Cardiology Division, San Francisco Veterans Affairs Medical Center, San Francisco, California
NovaCardia, Inc., San Diego, California
University of California, San Diego, California
View larger version (22K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 1 Flow Diagrams Depicting Study Protocols
(A) Acute decompensated heart failure (ADHF) patients with renal impairment. (B) ADHF patients who were resistant or refractory to diuretics. CrCl = creatinine clearance; IV = intravenous.
|
|
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 2 Urine Output in First 6 h
Cumulative urine volume (mean ± SEM) 6 h after initiation of placebo or KW-3902 in acute decompensated heart failure patients with renal impairment (*p = 0.02 vs. placebo).
|
|
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 3 Daily Administration of IV Diuretics
Daily dose of intravenous (IV) furosemide (mean ± SEM) administered to the placebo and 4 KW-3902 groups over the first 3 days of the study (*p < 0.05 vs. placebo).
|
|
View larger version (20K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 4 Change in Urine Output over 24 h
Change in hourly urine volume (mean ± SEM) through 24 h after dosing with placebo or KW-3902 in acute decompensated heart failure patients refractory/resistant to diuretics.
|
|
View larger version (21K):
[in this window]
[in a new window]
[Download PPT slide]
|
Figure 6 Change in CrCl over 24 h
Change in measured creatinine clearance (CrCl) (mean ± SEM) relative to baseline in acute decompensated heart failure patients refractory/resistant to diuretics (*p < 0.05 vs. baseline).
|
|
|
